Impacts of Metabolic Disruption, Body Mass Index and Inflammation on Cognitive Function in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine (P6-10.009)
In this study, we aim to investigate the efficacy of vortioxetine in improving cognitive deficits in individuals with Post-COVID-19 Condition (PCC), while accounting for the interaction of metabolic dysfunction, elevated inflammation, and body mass index (BMI).
Authors
- Angela T.H. Kwan (ORCID: https://orcid.org/0000-0003-4013-1112)
- Bing Cao (ORCID: https://orcid.org/0000-0001-5963-2676)
- Shakila Meshkat (ORCID: https://orcid.org/0000-0002-7010-1785)
- Joshua D. Rosenblat (ORCID: https://orcid.org/0000-0002-4773-2191)
- Lee Phan (ORCID: https://orcid.org/0000-0001-8183-0265)
- Roger Ho (ORCID: https://orcid.org/0000-0001-9629-4493)
- Sebastian Badulescu
- Kayla M. Teopiz (ORCID: https://orcid.org/0000-0001-8429-6563)
- Taeho Greg Rhee (ORCID: https://orcid.org/0000-0003-4961-3361)
- Felicia Ceban (ORCID: https://orcid.org/0000-0001-6815-7248)
- Ziji Guo
- Donovan A. Dev (ORCID: https://orcid.org/0009-0000-1412-0554)
- Roger S. McIntyre
Institutions
- Southwest University (CN)
- University of Ottawa (CA)
- University of Toronto (CA)
- Yale University (US)
- Brain and Cognition Discovery Foundation (CA)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000209055
- Primary Topic
- Intensive Care Unit Cognitive Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00